DNA methylation biomarker for cumulative lead exposure is associated with Parkinson’s disease

Lead, a known neurotoxicant, has previously received attention in Parkinson’s disease (PD) research, but epidemiologic studies have been limited in sample size and findings are equivocal. We generated two methylation-based biomarkers for cumulative tibia and patella bone-measured lead exposure in 15...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Kimberly C., Horvath, Steve, Del Rosario, Irish, Bronstein, Jeff M., Ritz, Beate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983295/
https://www.ncbi.nlm.nih.gov/pubmed/33752746
http://dx.doi.org/10.1186/s13148-021-01051-3
_version_ 1783667878885588992
author Paul, Kimberly C.
Horvath, Steve
Del Rosario, Irish
Bronstein, Jeff M.
Ritz, Beate
author_facet Paul, Kimberly C.
Horvath, Steve
Del Rosario, Irish
Bronstein, Jeff M.
Ritz, Beate
author_sort Paul, Kimberly C.
collection PubMed
description Lead, a known neurotoxicant, has previously received attention in Parkinson’s disease (PD) research, but epidemiologic studies have been limited in sample size and findings are equivocal. We generated two methylation-based biomarkers for cumulative tibia and patella bone-measured lead exposure in 1528 PD patients and 1169 controls. PD status was associated with increased levels of the DNAm biomarker for tibia-lead levels. We estimated a meta-OR for PD of 1.89 per unit DNAm tibia-lead increase (95% CI 1.59, 2.24; p = 8.1E−13). The current study supports the notion that chronic and long-term lead exposure tracked via DNAm may contribute to PD pathogenesis.
format Online
Article
Text
id pubmed-7983295
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79832952021-03-22 DNA methylation biomarker for cumulative lead exposure is associated with Parkinson’s disease Paul, Kimberly C. Horvath, Steve Del Rosario, Irish Bronstein, Jeff M. Ritz, Beate Clin Epigenetics Short Report Lead, a known neurotoxicant, has previously received attention in Parkinson’s disease (PD) research, but epidemiologic studies have been limited in sample size and findings are equivocal. We generated two methylation-based biomarkers for cumulative tibia and patella bone-measured lead exposure in 1528 PD patients and 1169 controls. PD status was associated with increased levels of the DNAm biomarker for tibia-lead levels. We estimated a meta-OR for PD of 1.89 per unit DNAm tibia-lead increase (95% CI 1.59, 2.24; p = 8.1E−13). The current study supports the notion that chronic and long-term lead exposure tracked via DNAm may contribute to PD pathogenesis. BioMed Central 2021-03-22 /pmc/articles/PMC7983295/ /pubmed/33752746 http://dx.doi.org/10.1186/s13148-021-01051-3 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Short Report
Paul, Kimberly C.
Horvath, Steve
Del Rosario, Irish
Bronstein, Jeff M.
Ritz, Beate
DNA methylation biomarker for cumulative lead exposure is associated with Parkinson’s disease
title DNA methylation biomarker for cumulative lead exposure is associated with Parkinson’s disease
title_full DNA methylation biomarker for cumulative lead exposure is associated with Parkinson’s disease
title_fullStr DNA methylation biomarker for cumulative lead exposure is associated with Parkinson’s disease
title_full_unstemmed DNA methylation biomarker for cumulative lead exposure is associated with Parkinson’s disease
title_short DNA methylation biomarker for cumulative lead exposure is associated with Parkinson’s disease
title_sort dna methylation biomarker for cumulative lead exposure is associated with parkinson’s disease
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983295/
https://www.ncbi.nlm.nih.gov/pubmed/33752746
http://dx.doi.org/10.1186/s13148-021-01051-3
work_keys_str_mv AT paulkimberlyc dnamethylationbiomarkerforcumulativeleadexposureisassociatedwithparkinsonsdisease
AT horvathsteve dnamethylationbiomarkerforcumulativeleadexposureisassociatedwithparkinsonsdisease
AT delrosarioirish dnamethylationbiomarkerforcumulativeleadexposureisassociatedwithparkinsonsdisease
AT bronsteinjeffm dnamethylationbiomarkerforcumulativeleadexposureisassociatedwithparkinsonsdisease
AT ritzbeate dnamethylationbiomarkerforcumulativeleadexposureisassociatedwithparkinsonsdisease

Ejemplares similares